… our study, 62% NSCLC patients had skin rash and 46% had diarrhea, which is consistent with
previous reports in randomized controlled trials. … toxicities in patients treated with Gefitinib. …

… -carboplatin chemotherapy to gefitinib significantly prolonged progression free and overall
survival but also increased toxicity. Pemetrexed-carboplatin-gefitinib represents a new …

… property, clinical efficacy, and safety of gefitinib in major clinical trials and post-… clinical
activity over gefitinib. In terms of the most common toxicities of skin reaction and diarrhea, gefitinib …

… Two of the earliest gefitinib clinical studies were Phase I dose-escalating trials conducted in
… effects reported during gefitinib administration is pulmonary toxicity, specifically interstitial …

… from 52 randomized clinical trials. BMJ 311: 899-909, 1995. 4 Grilli R, Oxyman AD and Julian
JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? …

… studies to better quantify the toxicities and clinical benefits of … Medical Library using the
keywords “EGFR mutation” and “gefitinib” and limiting the results to randomized clinical trials. …

… agents without toxicities after 2 weeks of receiving gefitinib had the gefitinib dose escalated
to … We report the first clinical trial with gefitinib, a small-molecule TKI of EGFR, in the treatment …

… phase II clinical trial evaluating neoadjuvant gefitinib given … only be established by a
randomized trial and even then, may … Toxicity profiles differ, with gefitinib's main toxic effects skin …

… This study evaluated the efficacy and toxicity of 250 mg daily gefitinib in patients with … TKI
to produce grade 2 or greater cutaneous toxicity is currently undergoing testing in clinical trials. …

… In phase I trials, gefitinib is well tolerated, with a dose limiting toxicity observed at a dose
well … Although the IDEAL studies were not placebo controlled trials, the response rates and …